Anmeldung erfolgt in Kürze...
Details werden geladen...
FDA Expands Talazoparib Combo Indication in Prostate Cancer
The approval makes the PARP inhibitor available earlier in the line of treatment for some patients with metastatic disease.
Ähnliche Seiten
FDA Approves Dostarlimab for Rectal Cancer
https://www.medscape.com/viewarticle/fda-approves-dostarlimab-rectal-cancer-2026a10013c7FDA Expands Anktiva Approval in Bladder Cancer
https://www.medscape.com/viewarticle/fda-expands-anktiva-approval-bladder-cancer-2026a10012nhFDA Approves First Generic Hormone Therapy Patch
https://www.medscape.com/viewarticle/fda-approves-generic-hormone-therapy-patch-menopause-2026a10013v9Intratumoral Immunotherapy Draws Attention but Does It Work?
https://www.medscape.com/viewarticle/intratumoral-immunotherapy-draws-renewed-attention-does-it-2026a10012vxARPIs Tied to Equal PFS Benefits in Prostate Cancer
https://www.medscape.com/viewarticle/arpis-tied-equal-pfs-benefits-metastatic-prostate-cancer-2026a10011ei